🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our JAMA Dermatology viewpoint bitly.ws/3fSDp examining immunotherapy in localized melanoma. Big congrats to Hannah Rashdan in my lab for leading the piece, which was also a hot topic @ the most recent Melanoma Research meeting! Thx to Ade Adamson, MD MPP for his collab.

Very excited to share our Delphi consensus guidelines to diagnosing dermatologic immunotherapy toxicites. Incredible team effort from more than 30 experts, including Steven Chen 陳持威, MD, MPH, MHPEd Kerry Reynolds, Jarushka Naidoo, and Nicole LeBoeuf.

Extremely proud of the team, especially Guihong WAN, Sara Khattab, MD, and Wenxin Elmon Chen for our The Lancet Oncology study on multi-organ toxicities from checkpoint blockade, providing a roadmap for prognosticating outcomes via the lens of immunotherapy toxicities: tinyurl.com/yc3t7amf

Online First: Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study #immunotherapy #ICIs #irAEs thelancet.com/journals/lanon…

Super excited to share our The Lancet Oncology study identifying improved survival among patient clusters dominated by cutaneous and endocrine immunotherapy toxicities, which was also highlighted by ASCO (tinyurl.com/bdf2tepc). Thanks to my mentors Eugene Semenov, MD and Guihong WAN.

Proud to share our work on mortality outcomes in patients who received ICI and who were treated with dupilumab for cirAE management. Thankful for the support of my mentors Eugene Semenov, MD, Dr. Nicole LeBoeuf, and Guihong WAN